Schrodinger Financial Ratios
NASDAQ: SDGRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
27.28+0.89 (+3.37%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Schrodinger ratio analysis
Schrodinger earned a net margin of -40.4% in FY 2025, up from -90.2% a year earlier. Gross margin was 55.7% compared with a median of 58.1% over the prior 6 years. Return on equity reached -28.4%, meaning Schrodinger generated -0.28 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Schrodinger financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | 66.30 | — | — | — | — |
| Price / sales | 5.16 | 7.31 | 11.86 | 7.35 | 17.83 | 43.97 | — |
| Price / book | 3.63 | 3.60 | 4.68 | 2.97 | 4.41 | 7.62 | — |
| Gross margin | 55.7% | 63.6% | 64.9% | 55.8% | 47.6% | 58.7% | 57.4% |
| Operating margin | -65.2% | -100.8% | -81.9% | -81.1% | -80.8% | -56.4% | -45.3% |
| Net margin | -40.4% | -90.2% | 18.8% | -82.4% | -72.8% | -22.6% | -28.7% |
| Free cash flow margin | 4.9% | -79.3% | -69.3% | -70.6% | -56.4% | 13.2% | -32.6% |
| Return on equity (ROE) | -28.4% | -44.4% | 7.4% | -33.3% | -18.0% | -3.9% | — |
| Return on assets (ROA) | -14.2% | -22.7% | 5.1% | -21.7% | -13.3% | -3.3% | -15.8% |
| Current ratio | 2.75 | 3.31 | 4.25 | 4.91 | 6.85 | 9.33 | 2.63 |
| Revenue growth | 23.3% | -4.2% | 19.7% | 31.2% | 27.6% | 26.4% | — |
| EPS growth | — | -575.9% | — | — | — | — | — |